| Patients with AML exhibit high variability in response to drugs such as trametinib | |
| RAS status alone is not predictive of trametinib sensitivity in AML blasts | |
| High expression of myeloid differentiation genes, such as CD14, is strongly predictive of trametinib sensitivity in AML blasts |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.